Handelsbanken Fonder AB Trims Holdings in Cellebrite DI Ltd. $CLBT

Handelsbanken Fonder AB decreased its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 47.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,510,000 shares of the company’s stock after selling 1,390,000 shares during the quarter. Handelsbanken Fonder AB’s holdings in Cellebrite DI were worth $27,225,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wealth Enhancement Advisory Services LLC boosted its position in Cellebrite DI by 40.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 359,764 shares of the company’s stock valued at $6,652,000 after purchasing an additional 103,568 shares in the last quarter. Norwood Investment Partners LP acquired a new stake in Cellebrite DI in the third quarter worth about $4,274,000. TimesSquare Capital Management LLC acquired a new stake in Cellebrite DI in the third quarter worth about $11,217,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Cellebrite DI in the third quarter worth about $19,457,000. Finally, Wisconsin Capital Management LLC purchased a new position in shares of Cellebrite DI in the third quarter worth about $1,649,000. Institutional investors own 45.88% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on CLBT shares. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday. Needham & Company LLC reduced their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Finally, Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $21.75.

Cellebrite DI Stock Down 1.2%

Shares of CLBT opened at $13.46 on Wednesday. Cellebrite DI Ltd. has a 52-week low of $11.02 and a 52-week high of $19.98. The firm’s fifty day moving average is $13.47 and its two-hundred day moving average is $15.45. The stock has a market cap of $3.36 billion, a PE ratio of 48.07, a price-to-earnings-growth ratio of 1.63 and a beta of 1.15.

Insiders Place Their Bets

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of the business’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $12.77, for a total transaction of $161,642.66. Following the transaction, the executive owned 440,101 shares of the company’s stock, valued at approximately $5,620,089.77. The trade was a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold a total of 13,269 shares of company stock worth $169,592 over the last quarter. Insiders own 5.70% of the company’s stock.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.